Table 3 First-line chemotherapy regimens for 109 patients with metastatic nonmucinous appendiceal adenocarcinoma
Regimen | Number of patients (%) |
|---|---|
Oxaliplatin-based | 60 (55) |
FOLFOX or XELOX | 18 (17) |
FOLFOX or XELOX + bevacizumab | 39 (36) |
FOLFOX or XELOX + cetuximab | 2 (2) |
EOX | 1 (1) |
Irinotecan-based | 29 (27) |
FOLFIRI | 5 (5) |
Irinotecan alone | 3 (3) |
FOLFIRI + cetuximab | 2 (2) |
FOLFIRI + bevacizumab | 12 (11) |
FOLFIRI + bevacizumab + cetuximab | 1 (1) |
FOLFIRI + thalidomide | 1 (1) |
Irinotecan + cisplatin | 4 (4) |
Irinotecan + cetuximab | 1 (1) |
Fluoropyrimidine alone | 13 (12) |
Other | 7 (6) |
Irinotecan + oxaliplatin + bevacizumab | 1 (1) |
Carboplatin + paclitaxel | 1 (1) |
5-FU or capecitabine + cisplatin | 4 (4) |
5-FU + interferon | 1 (1) |